Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)
Fita Rahmawati
Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Hubungan Penyakit Diabetes Melitus dan Penggunaan Antidiabetes terhadap Rekurensi pada Pasien Kanker Payudara Fitri Wulandari; Kartika Widayati; Fita Rahmawati
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 9, No 4
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (617.823 KB) | DOI: 10.22146/jmpf.48069

Abstract

Breast cancer is the cancer with the most prevalence of 43.3% and the mortality rate that reaches 12.9%. The prognosis of breast cancer can be affected by diabetes mellitus (DM), so that efforts to control DM through antidiabetic therapy are very necessary, but antidiabetic therapy is also reported to be associated with the prognosis of breast cancer. The purpose of this study was to determine the relationship of diabetes and antidiabetic use to recurrence in breast cancer patients. This study used a retrospective cohort design, involving 176 female non-metastatic breast cancer patients who received chemotherapy, consisting of 88 patients with DM and 88 non-DM patients. The exposures in the study were diabetes mellitus and the types of antidiabetic drugs (metformin and non metformin based therapy), while the study output was the recurrence of breast cancer. The research data was obtained from the patient’s medical records at RSUP Dr. Sardjito Yogyakarta. Research analysis used Chi-square, Kaplan Meier method and Cox-regression to estimate Hazard Ratio with 95% confidence interval. The results showed DM in breast cancer patients was associated with increased the risk of recurrence (HR 2,458; 95% CI 1,571-3,846, log rank test P=0,000), while the use of antidiabetic types (metformin and nonmetformin) to control DM in breast cancer patients was not associated with the risk of recurrence (HR 1.391; 95% CI 0.816 - 2.370, log rank test P=0.210). Further research is warranted by monitoring blood glucose levels regularly.
Kajian Efek Samping Obat Kemoterapi Dosetaksel pada Kanker Payudara di RS Bhayangkara Kediri Nunuk Wijayanti; Fita Rahmawati; Pramugyono Pramugyono
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 13, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.83782

Abstract

Docetaxel is a chemotherapy drug for breast cancer. Chemotherapy can cause various side effects. This study aims to provide an overview of the side effects of non-hematological and hematological drugs from the use of docetaxel chemotherapy. The non-hematological side effects observed included dermatological disorders, endocrine and metabolic disturbances, and gastrointestinal-related disorders. While the observed hematological side effects included anemia, thrombocytopenia, leukopenia, and neutropenia. The study used a cross-sectional design with prospective data collection on 45 patients undergoing a docetaxel chemotherapy regimen with a dose of 100 mg/m2 at Bhayangkara Hospital, Kediri from January 2022 - March 2023. Data collection was carried out through medical records and then identification of drug side effects was carried out through pharmacist discussion with a consultant clinician in oncology. Data evaluation was carried out descriptively in the form of percentages. The most common non-hematological side effects were hair loss, which reached 80%, followed by skin hypersensitivity reactions, which reached 73.3%, and nail changes, which reached 48.9%. At the mild severity level (grade 1), skin hypersensitivity reactions were the highest at 73.3%, followed by hair loss at 64.4%. The most significant hematological side effect is anemia. Patients experienced anemia with grade 1 as much as 37.3% and 2.2% occurred in grade 2. The side effects of docetaxel that occurred in this study were overall in the mild (grade 1) and moderate (grade 2) categories. Most patients can still tolerate the symptoms of side effects that arise. Monitoring of drug side effects and prompt management of symptoms is necessary to reduce the severity and improve patient quality of life.
Co-Authors Fitri Wulandari Kartika Widayati Taroeno Hariadi Nunuk Wijayanti Pramugyono Pramugyono